PROGNOSTIC FACTORS FOR RESPONSE AND SURVIVAL WITH ALPHA-INTERFERON (IFN-A) THERAPY IN EARLY CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML)

被引：0
|
作者：
KANTARJIAN, H [1 ]
SMITH, T [1 ]
OBRIEN, S [1 ]
ROBERTSON, L [1 ]
KOLLER, C [1 ]
BERAN, M [1 ]
KEATING, M [1 ]
TALPAZ, M [1 ]
机构：
[1] MD ANDERSON CANC CTR,HOUSTON,TX
来源：
BLOOD | 1993年 / 82卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A378 / A378
页数：1
相关论文
共 50 条
  • [21] Late cytogenetic and molecular response to interferon-α (IFN-α) in chronic myelogenous leukemia (CML).
    Nosari, A
    Perego, R
    Pungolino, E
    Cornacchini, G
    Gargantini, L
    Morra, E
    BLOOD, 1998, 92 (10) : 627A - 627A
  • [22] Long-term follow-up results of alpha-interferon (alpha-IFN)-based regimens in patients with late chronic phase chronic myelogenous leukemia (CP-CML).
    Sacchi, S
    Kantarjian, H
    OBrien, S
    Keating, M
    Freireich, E
    Talpaz, M
    BLOOD, 1996, 88 (10) : 3531 - 3531
  • [23] Pilot study of interferon alpha receptor (IFN alpha R) expression in patients with chronic myelogenous leukemia (CML).
    Spielberger, R
    Snyder, D
    Forman, SJ
    Niland, J
    Nunez, R
    Domanski, PI
    Colamonici, O
    BLOOD, 1995, 86 (10) : 2100 - 2100
  • [24] Gene transfer of alpha interferon (IFN-alpha) into hematopoietic stem cells in chronic myelogenous leukemia (CML).
    Abraham, NG
    Cook, P
    Feldman, E
    Ahmed, T
    EXPERIMENTAL HEMATOLOGY, 1996, 24 (09) : 157 - 157
  • [25] PROLONGED SURVIVAL IN CHRONIC MYELOGENOUS LEUKEMIA AFTER CYTOGENETIC RESPONSE TO INTERFERON-ALPHA THERAPY
    KANTARJIAN, HM
    SMITH, TL
    OBRIEN, S
    BERAN, M
    PIERCE, S
    TALPAZ, M
    ROBERTSON, L
    KOLLER, C
    ESTEY, E
    KEATING, MJ
    ANNALS OF INTERNAL MEDICINE, 1995, 122 (04) : 254 - 261
  • [26] PROGNOSTIC FACTORS IN DIFFERENT STAGES OF CHRONIC MYELOGENOUS LEUKEMIA (CML)
    KANTARJIAN, HM
    LEUKEMIA, 1987, 1 (03) : 255 - 255
  • [27] LONG-TERM SURVIVAL IN CHRONIC MYELOGENOUS LEUKEMIA (CML) - ARE THERE ANY PROGNOSTIC FACTORS
    PRISCHL, F
    SCHWARZMEIER, J
    HAAS, O
    GRANINGER, W
    BLUT, 1984, 49 (03): : 224 - 224
  • [28] INTERFERON-ALPHA THERAPY FOR CHRONIC MYELOGENOUS LEUKEMIA
    WETZLER, M
    KANTARJIAN, H
    KURZROCK, R
    TALPAZ, M
    AMERICAN JOURNAL OF MEDICINE, 1995, 99 (04): : 402 - 411
  • [29] PROGNOSTIC FACTORS FOR RESPONSE TO CHEMOTHERAPY AND SURVIVAL IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN BLASTIC CRISIS (CML-BC)
    KANTARJIAN, H
    WALTERS, R
    KEATING, M
    TALPAZ, M
    MCCREDIE, K
    FREIREICH, E
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 194 - 194
  • [30] Sequential homoharringtonine (HHT) and interferon (IFN-A) produce high hematologic and cytogenetic response rates in Philadelphia chromosome positive (Ph) chronic myelogenous leukemia (CML).
    O'Brien, S
    Kantarjian, H
    Koller, C
    Andreeff, M
    Feldman, E
    Keating, M
    Beran, M
    Freireich, E
    Rios, MB
    Talpaz, M
    BLOOD, 1998, 92 (10) : 656A - 656A
12345